HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodies

AIDS Research and Human Retroviruses

Volumn 25, Issue 11, 2009, Pages 1165-1169

  Dieltjens, Tessa ^a   Loots, Nathalie ^a   Vereecken, Katleen ^a   Grupping, Katrijn ^a   Heyndrickx, Leo ^a   Bottieau, Emmanuel ^a   Vanham, Guido ^a,b   Davis, David ^c   Janssens, Wouter ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ARTICLE; DISEASE COURSE; GENE SEQUENCE; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHYLOGENY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

EID: 71949111977     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0161     Document Type: Article

References (15)

1. Beirnaert E, Nyambi P, Willems B, et al.: Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 2000;62:14-24.
2. Zhang PF, Cham F, Dong M, et al.: Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci USA 2007;104:10193-10198.
3. Davis D, Donners H, Willems B, et al.: Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases. J Med Virol 2003;71:332-342.
4. Dhillon AK, Donners H, Pantophlet R, et al.: Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007;81:6548-6562.
5. Connor RI, Chen BK, Choe S, and Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995;206: 935-944.
6. Montefiori DC: Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009;485:395-405.
7. Davis D, Stephens DM, Willers C, and Lachmann PJ: Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol 1990;71(Pt. 12):2889-2898.
8. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, and Kayman SC: The V1=V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004;78:5205-5215.
9. Sagar M, Wu X, Lee S, and Overbaugh J: Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006;80:9586-9598.
10. Ching LK, Vlachogiannis G, Bosch KA, and Stamatatos L: The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol 2008;82:949-956.
11. Ly A and Stamatatos L: V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 2000;74:6769-6776.
12. Moore PL, Gray ES, Choge IA, et al.: The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008;82:1860-1869.
13. Barker E, Mackewicz CE, Reyes-Teran G, et al.: Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998;92:3105-3114.
14. Blaak H, Brouwer M, Ran LJ, de Wolf F, and Schuitemaker H: In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis 1998;177: 600-610. (Pubitemid 28099873)
15. Emu B, Sinclair E, Hatano H, et al.: HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008;82:5398-5407.